This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I42.1 | Special Copayment Reduction: V127 (5 years) |
| B. Synonyms | Hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic subaortic stenosis (IHSS), hypertrophic obstructive cardiomyopathy (HOCM), hypertrophic cardiomyopathy (HCM) |
| C. Adult onset | Likelihood of first presentation in adulthood: high — typically presents in adolescence to the 30s, first detected through arrhythmia, syncope, or exercise intolerance, and some remain asymptomatic until middle age |
| 1. History | 1958 first description by Brock and Teare → 1960 Braunwald establishes the concept of LVOT obstruction → 1989 MYH7 linkage → 2022 FDA approval of mavacamten (first cardiac myosin inhibitor) |
| 2. Causes | Sarcomere protein gene variants account for ~60% of causes; the two genes MYH7 and MYBPC3 account for about 70% of the total; autosomal dominant inheritance; about 40% non-genetic |
| 3. Genetics | MYH7 (~35%), MYBPC3 (~35%), TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, etc.; variant diversity within the same gene; severe phenotype with double variants |
| 4. General epidemiology | Prevalence 1/200–500 (0.2%); annual incidence 0.5/100,000; a leading cause of sudden death in young athletes; equal in males and females, male predominance in some phenotypes |
| 5. Pathophysiology | Sarcomere hypercontractility → asymmetric septal hypertrophy → SAM (systolic anterior motion) → LVOT obstruction → diastolic dysfunction → arrhythmogenic substrate |
| 6. Symptoms | Exertional dyspnea, chest pain, syncope, palpitations; worsening with exercise; progressive heart failure (end stage); sudden death (typically in young athletes) |
| 7. Signs | Dynamic systolic murmur (increases with Valsalva and standing, decreases with squatting); bifid apical impulse; S4 gallop; mitral regurgitation murmur |
| 8. Screening | Echocardiography (septal thickness, LVOT pressure gradient, SAM); screening of first-degree relatives (age 12 and older, ECG + echo every 2–5 years); genetic testing |
| 9. Diagnosis | Echocardiography (LVH ≥ 15mm + LVOT pressure gradient ≥ 30mmHg at rest, ≥ 50mmHg provoked); cardiac MRI (detailed assessment of LGE and morphology); gene panel |
| 10. Treatment | First line: BB, non-DHP CCB; second line: mavacamten (Camzyos, 2022 FDA, 2024 AHA/ACC recommendation); SRT (myectomy, TASH); ICD after SCD risk assessment |
| 11. Prognosis | Annual mortality about 1% (specialized centers); relatively favorable when an ICD for SCD prevention is in place; end-stage heart failure (about 5% of all HCM) and sudden death are the main causes of death |
| 12. Prevention | Family screening; assessment of restrictions on competitive sports; ICD for those at high SCD risk; early rhythm control of atrial fibrillation; pregnancy counseling |
| 13. References | 2024 AHA/ACC HCM guideline, key mavacamten trials including EXPLORER-HCM and SEQUOIA-HCM, and 10 others |
The history of hypertrophic cardiomyopathy (HCM) begins in Britain in the late 1950s. In 1957, Donald Teare (UK) first described a distinctive cardiac lesion characterized by asymmetric septal hypertrophy at autopsy of young people who had died suddenly, and reported it in the British Heart Journal (1958) under the title "Asymmetrical hypertrophy of the heart in young adults". Teare was the first to propose that this lesion was familial.
In the same year, 1958, Sir Russell Brock, a cardiac surgeon at Hammersmith Hospital in London, described the clinical syndrome while operating on patients with muscular obstruction of the left ventricular outflow tract (LVOT). In 1960, Eugene Braunwald and colleagues at the US NIH first demonstrated a dynamic pressure gradient in the LVOT by left ventricular catheterization and showed that this obstruction is provoked or worsened by exercise, the Valsalva maneuver, isoproterenol administration, etc. Braunwald named it "idiopathic hypertrophic subaortic stenosis (IHSS)". This concept of dynamic obstruction became central to the understanding of HCM and the development of treatment strategies.
In the 1960s–70s, various names (IHSS, HOCM, MSS, etc.) were used interchangeably. In 1985, Wigle et al. compiled a comprehensive clinical classification, and a trend toward international unification under "hypertrophic cardiomyopathy (HCM)" emerged. The introduction and spread of echocardiography during this period enabled noninvasive diagnosis of HCM and greatly expanded clinical understanding. In particular, echocardiography clearly demonstrated that systolic anterior motion (SAM) of the mitral valve is the direct mechanism of LVOT obstruction.
The revolution in molecular genetics began when Jarcho et al. in 1989 and Geisterfer-Lowrance et al. in 1990 discovered HCM-causing mutations in MYH7 (the β-myosin heavy chain gene). Subsequently, as MYBPC3 (myosin-binding protein C-3) in 1995 and various sarcomere protein genes such as TNNT2, TNNI3, and TPM1 in the late 1990s were identified as causes of HCM, HCM was established as a "sarcomeric protein gene disease".
The most recent breakthrough in treatment is the FDA approval of mavacamten (Camzyos) in April 2022. It is the first cardiac myosin inhibitor, a drug with an unprecedented mechanism that directly targets sarcomere hypercontractility, the molecular cause of LVOT obstruction. The phase 3 EXPLORER-HCM trial (2020) demonstrated symptom improvement and reduction of the LVOT pressure gradient, and the 2024 AHA/ACC HCM guideline recommended mavacamten as Class IIa in adults intolerant of or with an insufficient response to first-line drugs (BB/CCB).
The most common cause of HCM is pathogenic variants in genes encoding sarcomere proteins. However, in about 40% of HCM patients, no pathogenic variant is identified by currently known gene panel testing; this is called "genotype-negative" HCM.
Sarcomere protein genes that cause HCM include MYH7 (β-myosin heavy chain), MYBPC3 (myosin-binding protein C-3), TNNT2 (cardiac troponin T), TNNI3 (cardiac troponin I), TPM1 (α-tropomyosin), MYL2 (regulatory myosin light chain), MYL3 (essential myosin light chain), and ACTC1 (cardiac α-actin). Of these, MYH7 and MYBPC3 account for about 70% of all HCM, and the remaining genes account for a small proportion. The mode of inheritance is mostly autosomal dominant, and theoretically the variant is transmitted to 50% of children. However, because penetrance is incomplete and expressivity is highly variable, the phenotype can differ greatly even among family members with the same variant.
"HCM phenocopies", which show left ventricular hypertrophy similar to HCM but without sarcomere variants, include Fabry disease (GLA gene, X-linked), Danon disease (LAMP2 gene, X-linked), PRKAG2 cardiomyopathy, and mitochondrial cardiomyopathy. These phenocopies can be clinically difficult to distinguish from HCM, but because specific treatments exist (e.g., enzyme replacement therapy in Fabry disease), differentiation is clinically important.
Some studies hypothesize that metabolic factors such as hypertension, diabetes, and obesity may act as promoters of phenotypic expression in genotype-negative HCM, but the cause-and-effect relationship is not yet clear. HCM in infants and neonates is associated with transient hypertrophy due to hyperinsulinism in infants of diabetic mothers (IDM) or with inherited metabolic diseases.
HCM is an inherited myocardial disease caused by mutations in sarcomere protein genes, and molecular genetic understanding is central to diagnosis, prognostic prediction, and family screening.
MYH7 encodes the β-myosin heavy chain expressed mainly in ventricular muscle, and mutations cluster in the actin-binding site and ATP hydrolysis site of the myosin head region. Features of MYH7-variant HCM: early onset (childhood to adolescence), severe phenotype (thick septum, high LVOT pressure gradient), high proportion of myocardial fibrosis, mostly missense variants. Early studies suggested that some variants such as Arg403Gln and Arg453Cys are associated with a particularly high risk of sudden death, but the prevailing view now is that risk is difficult to predict from a single variant alone.
MYBPC3 encodes a protein that stabilizes myosin filaments in the sarcomere A-band and is involved in regulating contraction. Features of MYBPC3-variant HCM: later age of onset (middle age and beyond), large variability of expression (asymptomatic to severe), many truncating variants (frameshift, nonsense, splice-site) (haploinsufficiency mechanism), overall better prognosis than MYH7-variant HCM, but diagnosis is delayed due to late onset. MYBPC3 founder variants (e.g., p.Arg502Gln) are relatively frequent in people from the Indian subcontinent.
TNNT2 (cardiac troponin T, 1q32.1) variants account for about 5% of HCM and are known for a disproportionate phenotype with high myocardial fibrosis and sudden death risk despite mild myocardial hypertrophy. TNNI3 variants (about 5% of HCM) are associated with severe diastolic dysfunction.
Patients carrying two or more pathogenic sarcomere variants ("compound heterozygosity/double mutation") tend to show earlier onset, more severe myocardial hypertrophy, higher sudden death risk, and a poorer clinical course than patients with a single variant. The prevalence of double variants is estimated at about 3–8% of HCM patients.
HCM was originally regarded as a rare disease, but echocardiographic screening studies revealed it to be far more common than thought.
Since Maron et al. reported a prevalence of 1/500 (0.2%) by echocardiography in a US adult population in 1995, HCM has been classified as the most common inherited heart disease. However, recent studies suggest that in the era of cardiomyopathy gene panels, the actual prevalence may be higher if carriers of gene variants are included. A US cohort study published in 2023 estimated that the prevalence may reach 1/200 when the population frequency of HCM-related gene variants is considered. More than about 20 million people worldwide are estimated to have HCM.
Traditionally, HCM has been reported to be diagnosed more often in men (M:F ≈ 2:1), but this may reflect diagnostic bias (a tendency for LVOT obstruction to be less prominent and symptoms to be atypical in women). Age of onset ranges from young children to people in their 80s, but symptoms typically first appear or the diagnosis is made in adolescence to the 30s. MYBPC3 variants often manifest after middle age. Limitations of epidemiological studies include the larger number of asymptomatic HCM carriers and the low rate of diagnosis during life.
HCM is the most common cardiac cause of sudden cardiac death (SCD) in young athletes under 35 (US data: about 36%). Proposed mechanisms are worsening of LVOT obstruction during exercise and induction of ventricular fibrillation by high-intensity exercise. In the Veneto region of Italy, arrhythmogenic right ventricular cardiomyopathy (ARVC) is a more common cause, but in North America HCM ranks first.
The pathophysiology of HCM is a multistep continuous process that begins with sarcomere dysfunction and proceeds to myocardial hypertrophy, diastolic dysfunction, LVOT obstruction, myocardial ischemia, and formation of an arrhythmogenic substrate.
In HCM, the common molecular consequence of pathogenic variants such as MYH7 and MYBPC3 is hyperactivation of myosin-actin cross-bridging. In normal myocardium, about 50–60% of myosin molecules remain in a "resting (OFF)" state to conserve energy. HCM variants reduce this resting pool (the "super-relaxed state"), so more myosin shifts into the active cross-bridge cycle. This hyperactivity causes increased contractility together with increased myocardial ATP consumption and diastolic dysfunction (delayed removal of cytoplasmic Ca²⁺). The mechanism of action of mavacamten is precisely to suppress this myosin hyperactivity and return more myosin to the resting state.
Sarcomere hypercontractility → myocardial energy shortage (energy depletion hypothesis, Ashrafian) → cardiomyocyte hypertrophy (especially asymmetric septal hypertrophy, ASH) → cell death (apoptosis) → myocardial fibrosis (interstitial and replacement fibrosis). Myocardial fibrosis is visualized on cardiac MRI as late gadolinium enhancement (LGE) and becomes the anatomical substrate of ventricular arrhythmias. The extent of LGE is associated with sudden death risk and heart failure progression.
Along with narrowing of the LVOT by asymmetric septal hypertrophy, the Venturi effect of systolic blood flow pulls the anterior mitral leaflet forward (toward the LVOT), producing systolic anterior motion (SAM). When SAM brings the anterior mitral leaflet into contact with the hypertrophied septum, the LVOT is dynamically obstructed and a pressure gradient forms. This obstruction is not fixed but dynamic, so it is worsened by increased heart rate, reduced preload (dehydration, standing), reduced afterload (vasodilators), and increased contractility (inotropes). An LVOT pressure gradient ≥ 30 mmHg at rest or ≥ 50 mmHg with provocation is the criterion for clinically significant obstruction.
Increased left ventricular stiffness due to myocardial hypertrophy and fibrosis → diastolic dysfunction (mainly delayed relaxation and reduced compliance) → elevated left atrial pressure → left atrial enlargement → formation of the anatomical and electrical substrate for atrial fibrillation. Atrial fibrillation occurs in about 20–25% of HCM patients and is an important cause of stroke risk and worsening heart failure.
Symptoms of HCM vary depending on the presence of LVOT obstruction (obstructive vs non-obstructive), the degree of diastolic dysfunction, and the presence of arrhythmias. Many HCM patients remain asymptomatic throughout life or experience only mild symptoms.
Exertional dyspnoea is the most common symptom of HCM (over 80%). LVOT obstruction + diastolic dysfunction → abrupt rise in left atrial pressure during exercise → pulmonary congestion → dyspnea. It is especially severe in obstructive HCM and improves quickly when exercise stops. Chest pain: occurs in about 25–50% of HCM; mechanisms include subendocardial ischemia (insufficient coronary blood flow relative to myocardial hypertrophy, reduced perfusion due to shortened diastole), anterior ischemia due to LVOT obstruction, and small vessel disease. It resembles typical angina but also occurs at rest, and coronary angiography shows no significant stenosis. Syncope or near-syncope: caused by worsening LVOT obstruction (reduced systemic vascular resistance during exercise → worsening obstruction → abrupt drop in cardiac output), ventricular tachycardia/fibrillation, and severe diastolic dysfunction. Syncope is a warning symptom of sudden death, and syncope during or immediately after exercise in particular is a high-risk sign.
Palpitation: caused by atrial fibrillation, premature ventricular contractions, non-sustained ventricular tachycardia, etc. In atrial fibrillation, loss of atrial contraction → reduced cardiac output → worsening symptoms. Sudden death: the most feared complication of HCM. The annual sudden death rate is about 0.5–1% in follow-up cohorts at modern HCM specialty centers, lower than past reports (about 3–5%). Most sudden deaths are due to ventricular fibrillation, and cases occurring during exercise in young athletes attract attention.
In about 5% of HCM patients, after decades, the disease progresses to a "dilated-hypokinetic stage (end-stage HCM or 'burnt-out HCM')" with reduced left ventricular systolic function. At this stage, the existing hypertrophic cardiomyopathy morphology converts to a phenotype resembling dilated cardiomyopathy, and the prognosis is poor.
The characteristic physical findings of HCM result from dynamic LVOT obstruction; the key point that distinguishes them from fixed stenosis is that the findings vary with examination maneuvers (changes in preload and afterload).
A coarse, harsh midsystolic ejection murmur (crescendo-decrescendo murmur) is heard at the lower left sternal border. Features of the LVOT obstruction murmur: the murmur becomes louder with the Valsalva maneuver (straining) or in the standing position (reduced preload → increased obstruction). Conversely, the murmur becomes softer in the squatting position (increased preload and afterload → reduced obstruction). This dynamic change is the key auscultatory finding that distinguishes it from fixed obstruction such as aortic stenosis. A mitral regurgitation murmur due to SAM accompanies it, and a holosystolic murmur radiating to the apex is heard together.
Bifid apical impulse: a finding in which a presystolic impulse due to atrial contraction (A wave) and the ventricular contraction impulse are separated and palpated twice. It reflects the process of forceful atrial contraction filling the stiff left ventricle.
Fourth heart sound (S4 gallop): a low-frequency sound produced when atrial blood fills a stiff ventricle with diastolic dysfunction. Very common in HCM. Carotid pulse waveform: "bisferiens pulse" — a characteristic pulse waveform produced when, after strong ejection in early left ventricular systole, ejection is impeded by mid-systolic LVOT obstruction.
Abnormalities on the 12-lead ECG are found in about 95% of HCM patients. Main findings: left ventricular hypertrophy (LVH) pattern, deep atypical Q waves (especially in inferior and lateral leads, reflecting myocardial fibrosis), left atrial enlargement, nonspecific ST-T changes (giant negative T waves in some). Non-sustained ventricular tachycardia (NSVT) on Holter monitoring is common in HCM and is one of the SCD risk factors.
Screening for HCM is important in individuals with a family history or in the context of pre-participation cardiac screening.
Screening echocardiography + 12-lead ECG is performed in first-degree relatives of patients with confirmed HCM. The 2024 AHA/ACC guideline and the ESC 2023 guideline strongly recommend family screening. Age to start screening: adolescence (age 12 and older) or earlier (if there are symptoms or ECG abnormalities). Repeat interval: every 12–18 months at ages 12–25, and every 2–5 years in adults. When a pathogenic gene variant is identified, echocardiographic follow-up is needed only in relatives who carry the variant, and non-carriers do not need follow-up.
A comprehensive HCM gene panel (MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL2, MYL3, ACTC1, etc.) is recommended for patients with a confirmed diagnosis. When a pathogenic variant is identified in the family, variant-specific cascade testing is the most efficient screening strategy. Genotype-positive, phenotype-negative carriers need follow-up echocardiography, and lifestyle guidance including restriction of high-intensity exercise is considered.
To prevent exercise-related sudden death due to HCM in competitive athletes, screening is performed with history taking (symptoms, family history) + cardiac auscultation + ECG (Italian approach) or echocardiography (some high-risk sports in the US). ECG screening increases the sensitivity of HCM detection but also increases the false-positive rate.
The core of HCM diagnosis is confirming left ventricular hypertrophy and LVOT obstruction after excluding secondary hypertrophy due to other causes (hypertension, aortic stenosis, athlete's heart, etc.).
Echocardiography is the first-line tool for diagnosing HCM. Diagnostic criteria: left ventricular wall thickness ≥ 15mm (adults) or Z-score ≥ +2 (children) not explained by other causes under appropriate loading conditions. In familial HCM, when a pathogenic variant is identified, 13–14mm can also be diagnostic. LVOT pressure gradient measurement: the resting gradient is measured by continuous-wave Doppler; if < 30 mmHg at rest, provoked measurement is performed with Valsalva, squat-to-stand, or exercise stress testing. ≥ 30 mmHg at rest or ≥ 50 mmHg with provocation is the criterion for significant obstruction. Assessment of the presence of SAM, the degree of mitral regurgitation, and left atrial size is also standard.
CMR is used when echocardiography cannot adequately assess the patient (poor acoustic window, hypertrophy in atypical locations such as apical hypertrophy), to quantify myocardial fibrosis (LGE), and for differential diagnosis (a basal inferolateral LGE pattern is specific in Fabry disease). LGE (late gadolinium enhancement) reflects myocardial replacement fibrosis, and LGE extent (> 15% of LV mass) is recognized as an independent sudden death risk factor in the 2024 AHA/ACC guideline.
Assessment of SCD risk factors is central to deciding on ICD indication. ESC HCM Risk-SCD calculator (HCM Risk-SCD score): calculates the predicted 5-year SCD risk using maximum LVH thickness, left atrial size, maximum LVOT pressure gradient, family history of SCD, presence of NSVT, presence of syncope, and age as variables (consider ICD if ≥ 6%). The AHA/ACC guideline (2024) recommends using the ESC calculator together with considering an ICD at a threshold of ≥ 2.5%/year. Additional risk factors: extensive LGE (> 15% of LV mass), LV apical aneurysm, history of multiple SCDs in the family.
The goals of HCM treatment are symptom relief, reduction of LVOT obstruction, arrhythmia management, and prevention of sudden death. The treatment algorithm is individualized according to the presence of LVOT obstruction, symptom severity, and SCD risk.
Non-selective beta-blockers (BB): metoprolol, propranolol, atenolol, etc. are first-line agents. Reduced heart rate → prolonged diastolic filling time (improved diastolic function) + reduced LVOT obstruction + arrhythmia prevention. Effective in relieving NYHA II–III symptoms in adults with obstructive HCM. Non-dihydropyridine calcium channel blockers (non-DHP CCB): verapamil is an alternative when BB is not tolerated or the response is insufficient. It has an additional effect on improving diastolic function and is particularly useful for improving dyspnea in non-obstructive HCM. However, caution is needed in severe obstruction (LVOT pressure gradient > 100 mmHg) and left heart failure. Disopyramide: a class 1a antiarrhythmic used in addition to BB or CCB; its strong negative inotropic effect reduces LVOT obstruction and is effective for symptom improvement.
Mavacamten, approved by the FDA in April 2022, is the first cardiac myosin inhibitor and marked a revolutionary turning point in the treatment of obstructive HCM (oHCM). Mechanism: directly targets sarcomere hyperactivation by inhibiting excessive myosin-actin cross-bridging. It returns more myosin to the energy-sparing super-relaxed state, improving LVOT obstruction and diastolic dysfunction. EXPLORER-HCM phase 3 trial (2020): in NYHA II–III oHCM patients already on BB/CCB, demonstrated a significant increase in pVO2, reduction of the LVOT pressure gradient, improvement in NYHA functional class, and reduction of HF biomarkers (NT-proBNP, cTnI) versus placebo. SEQUOIA-HCM trial (2024): demonstrated superiority of mavacamten alone even in BB/CCB-naive patients. The 2024 AHA/ACC HCM guideline gives a Class IIa recommendation in symptomatic adults with oHCM who respond insufficiently to or are intolerant of first-line therapy. Main precautions: risk of LVEF reduction (temporarily interrupt if < 50%), CYP2C19 metabolism (high burden), caution with interactions with strong CYP3A4/2C19 inducers, contraindicated in pregnancy. Prescription is made under a REMS (Risk Evaluation and Mitigation Strategy) program.
SRT is considered when symptoms persist despite maximal drug therapy and the LVOT pressure gradient is significant (≥ 50 mmHg). Surgical Septal Myectomy: surgery that resects part of the muscle of the hypertrophied ventricular septum; it is the "gold standard" SRT. Currently, 30-day mortality at HCM specialty centers is < 1%. Long-term results are excellent (sustained symptom relief and fewer arrhythmias at 10–20 years of follow-up). Preferred in young adults and children and with anatomical variants (when accompanied by abnormalities of mitral valve structure). Alcohol Septal Ablation (ASA/TASH): a catheter procedure in which ethanol is injected into a septal perforating artery to induce a controlled myocardial infarction of the hypertrophied septum, reducing LVOT obstruction. Less invasive, with LVOT gradient reduction similar to surgery in same-institution comparisons. Preferred in elderly patients and those at high surgical risk. Complications: complete atrioventricular block (permanent pacemaker required, 5–10%), procedure-related VT, coronary artery injury.
ICD (implantable cardioverter-defibrillator): the cornerstone of primary SCD prevention. In the 2024 AHA/ACC guideline, an ICD is considered when the HCM Risk-SCD score 5-year risk is ≥ 6% (ESC criterion) or ≥ 2.5%/year (AHA/ACC criterion), or when there is extensive LGE, an apical aneurysm, non-sustained ventricular tachycardia, etc. Atrial fibrillation: anticoagulation (NOAC preferred; strongly recommended even in paroxysmal atrial fibrillation because stroke risk is high), rhythm control (antiarrhythmic drugs, catheter ablation, electrical cardioversion).
The natural history of HCM is being reassessed as far more favorable than in the past. In modern cohorts treated at specialized HCM centers, annual mortality is about 0.5–1%, not greatly different from the general population.
Studies published in the 1970s–80s reported a high annual mortality of 3–5% for HCM, mainly reflecting selection bias toward severe patients referred to tertiary centers. Later, community-based cohort studies confirmed an annual mortality of less than 1%. The prognosis continues to improve with specialty center care, wider use of ICDs, and the introduction of new drug therapy (mavacamten).
In HCM patients with an implanted ICD, the annual rate of inappropriate shocks (about 4–5%) is a problem, but the rate of appropriate shocks (actually life-saving) is about 3–4% per year. In the high SCD risk group, the life-saving effect of ICDs is clear. S-ICD (subcutaneous ICD) allows SCD prevention without intravascular hardware and is increasingly preferred in young HCM patients.
Real-world data on mavacamten published in 2024–2025 confirmed a sharp reduction in the LVOT pressure gradient by 12 weeks and an improvement of ≥1 NYHA functional class in more than 75%. Sustained clinical benefit and reasonable safety were also reported at long-term (108-week) follow-up. A reduction in the need for SRT is also expected.
Because HCM is a genetic disease, primary prevention (preventing the occurrence of the disease itself) is not possible, but preventing complications and sudden death through genetic counseling and early detection is key.
Screening by echocardiography + ECG + symptom assessment is performed in all first-degree relatives of patients with confirmed HCM. When a pathogenic variant is identified, phenotype-negative carriers are identified through variant-specific cascade testing and followed regularly. HCM variant carriers planning pregnancy are counseled about preimplantation genetic diagnosis (PGT-M) or prenatal diagnosis options.
The past principle of prohibiting all competitive sports based on an HCM diagnosis alone was relaxed in the 2024 AHA/ACC guideline. Currently, participation in most sports can be considered in HCM patients without risk factors who are classified as low risk, and patients with an ICD also decide on sports participation through shared decision-making. However, those at high SCD risk (extensive LGE, inadequate response to SRT, history of arrhythmia) are still advised to refrain from high-intensity competitive sports.
Anticoagulation is strongly recommended for atrial fibrillation (including paroxysmal) accompanying HCM (NOAC recommended regardless of CHA2DS2-VASc score). Evidence is increasing that a rhythm control strategy is beneficial in preventing symptom worsening and heart failure progression due to atrial fibrillation.